Drug transporter pharmacogenetics in nucleoside-based therapies.
Article Details
- CitationCopy to clipboard
Errasti-Murugarren E, Pastor-Anglada M
Drug transporter pharmacogenetics in nucleoside-based therapies.
Pharmacogenomics. 2010 Jun;11(6):809-41. doi: 10.2217/pgs.10.70.
- PubMed ID
- 20504255 [ View in PubMed]
- Abstract
This article focuses on the different types of transporter proteins that have been implicated in the influx and efflux of nucleoside-derived drugs currently used in the treatment of cancer, viral infections (i.e., AIDS) and other conditions, including autoimmune and inflammatory diseases. Genetic variations in nucleoside-derived drug transporter proteins encoded by the gene families SLC15, SLC22, SLC28, SLC29, ABCB, ABCC and ABCG will be specifically considered. Variants known to affect biological function are summarized, with a particular emphasis on those for which clinical correlations have already been established. Given that relatively little is known regarding the genetic variability of the players involved in determining nucleoside-derived drug bioavailability, it is anticipated that major challenges will be faced in this area of research.
DrugBank Data that Cites this Article
- Drug Transporters
Drug Transporter Kind Organism Pharmacological Action Actions Lamivudine Canalicular multispecific organic anion transporter 1 Protein Humans UnknownNot Available Details Lamivudine Canalicular multispecific organic anion transporter 2 Protein Humans UnknownSubstrateDetails Lamivudine Multidrug resistance-associated protein 4 Protein Humans UnknownSubstrateDetails Lamivudine P-glycoprotein 1 Protein Humans UnknownSubstrateDetails Lamivudine Solute carrier family 22 member 2 Protein Humans UnknownSubstrateDetails Lamivudine Solute carrier family 22 member 3 Protein Humans UnknownSubstrateDetails